This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Colgate-Palmolive (CL) Lags Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Colgate-Palmolive (CL) delivered earnings and revenue surprises of -1.37% and -0.02%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Why Colgate-Palmolive (CL) Might Surprise This Earnings Season
by Zacks Equity Research
Colgate-Palmolive (CL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Buy 5 High-Flying Stocks Ahead of Q2 Earnings This Week
by Nalak Das
It will be prudent to invest in stocks that are likely to beat earnings estimates in the second quarter this week.
Colgate-Palmolive (CL) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Colgate-Palmolive (CL) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Things You Need to Know Before FEMSA's (FMX) Q2 Earnings
by Zacks Equity Research
FEMSA's (FMX) second-quarter 2019 results are likely to be impacted by ongoing cost headwinds, which should continue to hurt margins. However, its growth efforts might provide some respite.
Check Out Colgate's (CL) Probability to Beat in Q2 Earnings
by Zacks Equity Research
Colgate's (CL) growth efforts indicate that it will likely retain the robust bottom-line surprise trend. However, soft margins and adverse currency may be deterrents.
Can Colgate-Palmolive (CL) Keep the Earnings Surprise Streak Alive?
by Zacks Equity Research
Colgate-Palmolive (CL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Colgate (CL) to Expand Skin Care Range With Filorga Buyout
by Zacks Equity Research
Colgate (CL) to expand the personal care portfolio with the acquisition of skin care business of France-based Filorga.
Colgate's (CL) Growth Efforts Well on Track Amid Soft Margins
by Zacks Equity Research
Colgate's (CL) strong surprise trend, higher pricing, strong innovation and expansion efforts bode well. However, high input costs and currency headwinds concerns.
Soap & Cleaning Materials Industry Outlook Upbeat on New Products
by Rajani Lohia
The FMCG space is likely to gain from investment in brands, innovation, cost-containment and pricing actions. However, its struggles against higher raw material and transportation costs continue.
Procter & Gamble Moves Up the Charts: Will Growth Continue?
by Zacks Equity Research
Procter & Gamble (PG) emphasizes on improving its product portfolio through strategic initiatives. Also, the company is on track with its cost-saving plans.
Church & Dwight Sales to Gain on International Unit & More
by Zacks Equity Research
Church & Dwight's (CHD) top line has been impressive for a while, gaining from strong Consumer International unit, buyouts and innovation.
Newell Loses 22% YTD: Can Its Transformation Plan Aid Stock?
by Zacks Equity Research
Newell's (NWL) dismal sales surprise trend can be attributed to lower core sales and adverse foreign currency. Nevertheless, its Transformation Plan appears encouraging.
Will Archer Daniels' Strategic Growth Efforts Drive Stock?
by Zacks Equity Research
Archer Daniels' (ADM) soft Carbohydrate Solutions segment is concerning. Nevertheless, the company's growth efforts such as the Readiness program are commendable.
Here's Why Colgate (CL) Deserves a Place in Your Portfolio
by Zacks Equity Research
Colgate (CL) exhibits strong surprise trend, owing to accelerated investments in brands, higher pricing and strong innovation along with expansion in new markets and channels.
Factors Likely to Influence Brown-Forman's (BF.B) Q4 Earnings
by Zacks Equity Research
Brown-Forman's (BF.B) Q4 results are likely to benefit from robust brand portfolio. However, tariff-related costs are hurting underlying net sales and gross margin.
Colgate-Palmolive (CL) Up 3.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Colgate-Palmolive (CL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Procter & Gamble (PG) Surges 47% in a Year: More Room to Run?
by Zacks Equity Research
Procter & Gamble (PG) stock reflects immense growth potential, backed by ongoing initiatives to improve productivity. However, strained margins and currency headwinds remain deterrents.
Here's Why Colgate-Palmolive (CL) is a Great Momentum Stock to Buy
by Zacks Equity Research
Does Colgate-Palmolive (CL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Church & Dwight (CHD) Q1 Earnings Beat, Organic Sales Up
by Zacks Equity Research
Church & Dwight's (CHD) earnings and sales improve in Q1. Management raises net sales view, considering the buyout of FLAWLESS.
Colgate (CL) Hits 52-Week High: What's Behind the Rally?
by Zacks Equity Research
Colgate's (CL) investments in brands, higher pricing and strong innovation along with expansion in new markets and channels bode well. Also, the company is on track with its savings program.
Colgate (CL) Q1 Earnings & Sales Top Estimates, Stock Up
by Zacks Equity Research
Colgate (CL) delivers top and bottom-line beat in first-quarter 2019, benefiting from favorable pricing and volume growth. However, adverse currency remains a hurdle.
UN or CL: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
UN vs. CL: Which Stock Is the Better Value Option?
Factors Likely to Shape Colgate's (CL) Q1 Earnings Outcome
by Zacks Equity Research
Colgate's (CL) growth efforts make us confident that it will likely retain the robust bottom-line surprise trend. However, soft margins and adverse currency may be deterrents.
Earnings Preview: Colgate-Palmolive (CL) Q1 Earnings Expected to Decline
by Zacks Equity Research
Colgate-Palmolive (CL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.